The Swiss company revealed that the new addition to Capsugel’s range will be made available in hard-gelatin and hydroxypropyl methylcellulose (HPMC) form, the latter being available in 50 colour variations.
Nicolas Madit business development manager at Lonza first outlined why the product was needed: “Ideally, the commercial colour choice will be finalised prior to the start of the development phase. But this is not always the case, and any change to the colour composition could require starting from the beginning with new stability testing.”
“That, needless to say, would result in a loss of time, money and valuable resources”, Madit concluded.
Rather than having to maintain one colour, the spokesperson explained that Capsugel Colorista allows company to test for stability and compatibility testing before a company needs to make a firm decision on which colour to move forward with commercially.
When asked what makes this approach attractive, Madit noted that it aids in the “flexibility” of product development, as well as being “time-efficient”.
Lonza purchased the Capsugel business at the end of 2016 for $5.5bn (€4.73bn) and the impact the newly-integrated business had made on revenue was made clear by full year financials posted earlier this year.
The company reported sales that were 23.5% higher than previous annual results for 2016; in a statement released alongside the financials, the company said: “With less than six months on Lonza’s books, Capsugel has already shown its potential to add to Lonza’s growth.”